I'm convinced that in few years there will be no primary or secondary prophylaxis using ASA. We will treat our high risk patients with ticagrelor in both indications. I do not know any data regarding your question mainly because ASA has an traditionally established position and no one will be interested to conduct such a study. The data regarding ticagrelor are much more promising than those of clopidogrel or prasugrel.
I'm convinced that in few years there will be no primary or secondary prophylaxis using ASA. We will treat our high risk patients with ticagrelor in both indications. I do not know any data regarding your question mainly because ASA has an traditionally established position and no one will be interested to conduct such a study. The data regarding ticagrelor are much more promising than those of clopidogrel or prasugrel.